Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.33 and traded as high as $1.53. Microbot Medical shares last traded at $1.49, with a volume of 374,393 shares trading hands.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price objective on Microbot Medical from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Friday, January 24th.
Get Our Latest Report on MBOT
Microbot Medical Stock Down 7.0 %
The company has a market cap of $48.82 million, a P/E ratio of -1.74 and a beta of 1.40. The company has a 50 day moving average price of $1.70 and a 200-day moving average price of $1.35.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, research analysts expect that Microbot Medical Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Trading of Microbot Medical
An institutional investor recently raised its position in Microbot Medical stock. Geode Capital Management LLC increased its stake in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) by 7.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 142,659 shares of the biotechnology company's stock after acquiring an additional 10,442 shares during the quarter. Geode Capital Management LLC owned approximately 0.70% of Microbot Medical worth $160,000 at the end of the most recent quarter. 16.30% of the stock is currently owned by institutional investors.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Stories
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
